Enhanced disulphide bond stability contributes to the once-weekly profile of insulin icodec
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Enhanced disulphide bond stability contributes to the once-weekly profile of insulin icodec ; volume:15 ; number:1 ; day:20 ; month:7 ; year:2024 ; pages:1-11 ; date:12.2024
Nature Communications ; 15, Heft 1 (20.7.2024), 1-11, 12.2024
- Classification
-
Medizin, Gesundheit
- Creator
-
Hubálek, František
Cramer, Christian N.
Helleberg, Hans
Johansson, Eva
Nishimura, Erica
Schluckebier, Gerd
Steensgaard, Dorte Bjerre
Sturis, Jeppe
Kjeldsen, Thomas B.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-024-50477-9
- URN
-
urn:nbn:de:101:1-2410062122547.623638243258
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hubálek, František
- Cramer, Christian N.
- Helleberg, Hans
- Johansson, Eva
- Nishimura, Erica
- Schluckebier, Gerd
- Steensgaard, Dorte Bjerre
- Sturis, Jeppe
- Kjeldsen, Thomas B.
- SpringerLink (Online service)
Other Objects (12)
Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
Treatment responses with once-weekly teriparatide therapy for osteoporosis
Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes
Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study
Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
Treatment responses with once-weekly teriparatide therapy for osteoporosis
Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes
Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study
Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
Treatment responses with once-weekly teriparatide therapy for osteoporosis
Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes